For research use only. Not for therapeutic Use.
Avatrombopag（Cat No.:I004127）is an oral thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic liver disease scheduled for a medical procedure and in individuals with chronic immune thrombocytopenia (ITP). By stimulating the thrombopoietin receptor, Avatrombopag promotes platelet production in the bone marrow, increasing platelet counts and reducing the risk of bleeding. Its targeted mechanism allows for effective management of low platelet levels without the need for platelet transfusions. Avatrombopag offers a convenient, non-invasive treatment option that improves patient outcomes and enhances safety in thrombocytopenia management.
| Catalog Number | I004127 |
| CAS Number | 570406-98-3 |
| Molecular Formula | C29H34Cl2N6O3S2 |
| Purity | 98% |
| Target | Thrombopoietin Receptor |
| Target Protein | |
| Solubility | DMSO: ≥ 32 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EC50: 3.3 nM (TPO receptor) |
| IUPAC Name | 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid |
| InChI | InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) |
| InChIKey | OFZJKCQENFPZBH-UHFFFAOYSA-N |
| SMILES | C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl |
| Reference | </br>1:Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han D.Clin Pharmacol Drug Dev. 2017 Mar 24. doi: 10.1002/cpdd.349. [Epub ahead of print] PMID: 28339166 </br>2:Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. Terrault NA, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins TM.J Hepatol. 2014 Dec;61(6):1253-9. doi: 10.1016/j.jhep.2014.07.007. Epub 2014 Jul 15. PMID: 25048952 </br>3:A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J.Blood. 2014 Jun 19;123(25):3887-94. doi: 10.1182/blood-2013-07-514398. Epub 2014 May 6. PMID: 24802775 Free Article |
